Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body's native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties - remarkable protein production, selective tissue targeting, and fine control of their cellular environment - to forge a new category of cell therapy. These medicines are designed to be durable, re-dosable and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, MD, and Richard James, PhD, Be Biopharma is re-imagining medicine based on the power of B cell therapy.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/22/20	$52,000,000	Series A	Alta Partners Atlas Venture Longwood Fund RA Capital Management Takeda Ventures	undisclosed
10/22/24	$82,000,000	Venture	Alta Partners ARCH Venture Partners Atlas Venture Bristol Myers Squibb Longwood Fund RA Capital Management Takeda Digital Ventures	undisclosed